BAJAJ BROKING

Notification
No new Notification messages
Wagons Learning IPO is Open!
Apply for the Wagons Learning IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

940

500126

PGHL

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

PROCTER & GAMBLE HEALTH L performance

Today’s low

Today’s high

₹ 5045.50 ₹ 5150.00
₹ 5082.00

52 week low

52 week high

₹ 4639.25 ₹ 5850.00
₹ 5082.00

Open Price

₹ 5103.00

Prev. Close

₹ 5111.50

Volume (Shares)

7156.00

Total traded value

₹ 363.66

Upper Circuit

₹ 6133.50

Lower Circuit

₹ 4089.50

info

PROCTER & GAMBLE HEALTH L Share Price Update

As of the latest trading session, PROCTER & GAMBLE HEALTH L share price is currently at ₹ 5052, which is down by ₹ -59.50 from its previous closing. Today, the stock has fluctuated between ₹ 5045.50 and ₹ 5150.00. Over the past year, PROCTER & GAMBLE HEALTH L has achieved a return of 3.50 %. In the last month alone, the return has been -1.41 %. Read More...

PROCTER & GAMBLE HEALTH L fundamentals


  • Market cap (Cr)

    8,435.80

  • P/E Ratio (TTM)

    35.59

  • Beta

    0.45

  • Book Value / share

    367.76

  • Return on equity

    31.18%

  • EPS (TTM)

    147.87

  • Dividend yield

    5.13%

  • Net profit/quarter (Cr)

    90.90

info icon alternate text
  • Market cap (Cr)

    8,420.30

  • P/E Ratio (TTM)

    35.59

  • Beta

    0.42

  • Book Value / share

    367.76

  • Return on equity

    31.18%

  • EPS (TTM)

    147.87

  • Dividend yield

    5.13%

  • Net profit/quarter (Cr)

    90.90

info icon alternate text

PROCTER & GAMBLE HEALTH L Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 309.77
Operating Expense 192.04
Net Profit 90.90
Net Profit Margin (%) 29.34
Earnings Per Share (EPS) 54.76
EBITDA 127.39
Effective Tax Rate (%) 25.30
Particulars SEP 2024 (Values in Cr)
Revenue 313.41
Operating Expense 205.29
Net Profit 82.33
Net Profit Margin (%) 26.26
Earnings Per Share (EPS) 49.60
EBITDA 117.32
Effective Tax Rate (%) 26.09
Particulars JUN 2024 (Values in Cr)
Revenue 283.88
Operating Expense 242.98
Net Profit 16.78
Net Profit Margin (%) 5.91
Earnings Per Share (EPS) 9.50
EBITDA 30.18
Effective Tax Rate (%) 26.50
Particulars MAR 2024 (Values in Cr)
Revenue 252.48
Operating Expense 192.03
Net Profit 46.56
Net Profit Margin (%) 18.44
Earnings Per Share (EPS) 28.00
EBITDA 69.71
Effective Tax Rate (%) 25.76
Particulars DEC 2023 (Values in Cr)
Revenue 309.97
Operating Expense 215.43
Net Profit 72.07
Net Profit Margin (%) 23.25
Earnings Per Share (EPS) 43.40
EBITDA 106.83
Effective Tax Rate (%) 27.72
Particulars JUN 2024 (Values in Cr)
Revenue 1151.26
Operating Expense 873.38
Net Profit 200.98
Net Profit Margin (%) 17.45
Earnings Per Share (EPS) 121.07
EBITDA 301.44
Effective Tax Rate (%) 26.46
Particulars JUN 2023 (Values in Cr)
Revenue 1229.62
Operating Expense 933.81
Net Profit 229.47
Net Profit Margin (%) 18.66
Earnings Per Share (EPS) 138.23
EBITDA 343.07
Effective Tax Rate (%) 26.96
Particulars JUN 2022 (Values in Cr)
Revenue 1114.41
Operating Expense 874.22
Net Profit 192.52
Net Profit Margin (%) 17.27
Earnings Per Share (EPS) 115.98
EBITDA 280.87
Effective Tax Rate (%) 24.01
Particulars JUN 2021 (Values in Cr)
Revenue 1008.73
Operating Expense 793.55
Net Profit 176.80
Net Profit Margin (%) 17.52
Earnings Per Share (EPS) 106.50
EBITDA 264.12
Effective Tax Rate (%) 24.21
Particulars JUN 2020 (Values in Cr)
Revenue 1355.86
Operating Expense 1069.90
Net Profit 254.08
Net Profit Margin (%) 18.73
Earnings Per Share (EPS) 153.10
EBITDA 384.30
Effective Tax Rate (%) 28.39
Particulars JUN 2024 (Values in Cr)
Book Value / Share 324.24
ROE % 31.18
ROCE % 39.76
Total Debt to Total Equity 0.02
EBITDA Margin 26.18
Particulars JUN 2023 (Values in Cr)
Book Value / Share 452.34
ROE % 33.56
ROCE % 43.16
Total Debt to Total Equity 0.01
EBITDA Margin 27.90
Particulars JUN 2022 (Values in Cr)
Book Value / Share 371.38
ROE % 29.17
ROCE % 35.97
Total Debt to Total Equity 0.01
EBITDA Margin 25.20
Particulars JUN 2021 (Values in Cr)
Book Value / Share 423.92
ROE % 21.96
ROCE % 27.53
Total Debt to Total Equity 0.00
EBITDA Margin 26.18
Particulars JUN 2020 (Values in Cr)
Book Value / Share 545.99
ROE % 13.85
ROCE % 18.81
Total Debt to Total Equity 0.00
EBITDA Margin 28.34
Particulars JUN 2024 (Values in Cr)
Cash & Short Term Investments 244.36
Total Assets 794.36
Total Liabilities 794.36
Total Equity 538.24
Share Outstanding 16599382
Price to Book Ratio 15.57
Return on Assets (%) 25.30
Return on Capital (%) 37.34
Particulars JUN 2023 (Values in Cr)
Cash & Short Term Investments 440.22
Total Assets 1101.19
Total Liabilities 1101.19
Total Equity 750.89
Share Outstanding 16599382
Price to Book Ratio 11.60
Return on Assets (%) 20.83
Return on Capital (%) 30.56
Particulars JUN 2022 (Values in Cr)
Cash & Short Term Investments 324.53
Total Assets 888.12
Total Liabilities 888.12
Total Equity 616.49
Share Outstanding 16599382
Price to Book Ratio 11.27
Return on Assets (%) 21.67
Return on Capital (%) 31.23
Particulars JUN 2021 (Values in Cr)
Cash & Short Term Investments 468.91
Total Assets 986.16
Total Liabilities 986.16
Total Equity 703.71
Share Outstanding 16599382
Price to Book Ratio 13.20
Return on Assets (%) 17.92
Return on Capital (%) 25.12
Particulars JUN 2020 (Values in Cr)
Cash & Short Term Investments 639.09
Total Assets 1175.74
Total Liabilities 1175.74
Total Equity 906.34
Share Outstanding 16599382
Price to Book Ratio 7.45
Return on Assets (%) 21.61
Return on Capital (%) 28.03
Particulars JUN 2024 (Values in Cr)
Net Income 273.32
Cash from Operations 313.47
Cash from Investing -6.87
Cash from Financing -418.10
Net change in Cash -196.69
Free Cash Flow 335.20
Particulars JUN 2023 (Values in Cr)
Net Income 314.20
Cash from Operations 325.67
Cash from Investing -21.50
Cash from Financing -98.49
Net change in Cash 116.02
Free Cash Flow 368.15
Particulars JUN 2022 (Values in Cr)
Net Income 253.37
Cash from Operations 233.38
Cash from Investing -25.54
Cash from Financing -288.63
Net change in Cash -144.65
Free Cash Flow 271.30
Particulars JUN 2021 (Values in Cr)
Net Income 233.28
Cash from Operations 315.38
Cash from Investing -32.27
Cash from Financing -386.63
Net change in Cash -171.64
Free Cash Flow 367.96
Particulars JUN 2020 (Values in Cr)
Net Income 354.85
Cash from Operations 336.96
Cash from Investing 164.64
Cash from Financing -883.41
Net change in Cash -483.40
Free Cash Flow 360.22
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 19.60 1.99 279.41 34.11 / 77.70
BLISS GVS PHARMA LTD 119.00 15.60 1.24 1253.91 92.25 / 184.95
CIPLA LTD 1549.65 25.08 4.41 125155.99 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 260.70 21.60 2.64 767.27 145.00 / 449.00
GLAXOSMITHKLINE PHARMA LT 2959.45 58.70 29.97 50134.87 1924.30 / 3147.45
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 21.96 6.19 279.41 34.11 / 77.70
AMRUTAJAN HEALTH LTD 692.80 40.61 6.72 2002.93 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8665.50 129.24 31.88 21663.75 5000.00 / 9199.00
BLISS GVS PHARMA LTD 119.00 15.45 1.22 1253.91 92.25 / 184.95

PROCTER & GAMBLE HEALTH L Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
5082.00 -0.57 redarrow
red-green-graph indicator
16 Bearish
0 Bullish
  • 5 Days 5116.50
  • 26 Days 5189.90
  • 10 Days 5145.30
  • 50 Days 5223.40
  • 12 Days 5153.40
  • 100 Days 5248.10
  • 20 Days 5177.00
  • 200 Days 5229.10
5105.00 PIVOT

First Support

5071.50

First Resistance

5145.00

Second Support

5031.50

Second Resistance

5178.50

Third Support

4998.00

Third Resistance

5218.50

RSI

43.07

ADX

9.48

MACD

-36.51

Williams % R

-86.53

Commodity Channel Index (CCI)

-109.48

Date

2025-04-30

Week

9755.00

Same Day

4011.00

Month

5697.00

1 Year

0.46

3 Year

0.35

Over 1 Month

-1.41%

down

Over 1 Year

3.50%

down

Over 3 Months

-3.94%

down

Over 3 Years

4.80%

down

Over 6 Months

0.51%

down

Over 5 Years

3.32%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

PROCTER & GAMBLE HEALTH L shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
27.1%
Promoter Holdings
51.81%
FII
6.87%
DII
14.2%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Procter And Gamble Overseas India B.v. 8601071.0 (51.82%) Shareholding of Promoter and Promoter Group
Nippon Life India Trustee Ltd-a/c Nippon India Sma 680942.0 (4.1%) Public Shareholding
Icici Prudential Smallcap Fund 461983.0 (2.78%) Public Shareholding
Life Insurance Corporation Of India 336667.0 (2.03%) Public Shareholding
Uti-mnc Fund 314895.0 (1.9%) Public Shareholding
Merck Internationale Beteiligungen Gmbh 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Emedia Export Company 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Chemitra Gesellschaft Mit Beschrankter Haftung 0.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

PROCTER & GAMBLE HEALTH L corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
14 Feb 2024 50.0 Interim 14 Feb 2024 Equity shares
14 Feb 2024 150.0 Special 14 Feb 2024 Equity shares
23 Nov 2023 50.0 Final 24 Nov 2023 Equity shares
13 Feb 2023 45.0 Interim 13 Feb 2023 Equity shares
15 Nov 2022 11.5 Final 17 Nov 2022 Equity shares
12 May 2022 41.0 Interim 13 May 2022 Equity shares
02 Nov 2021 40.0 Final 05 Nov 2021 Equity shares
02 Nov 2021 90.0 Special 05 Nov 2021 Equity shares
18 Nov 2020 42.0 Final 20 Nov 2020 Equity shares
18 Nov 2020 188.0 Special 20 Nov 2020 Equity shares
23 May 2019 24.0 Final 25 May 2019 Equity shares
23 May 2019 416.0 Special 25 May 2019 Equity shares
21 May 2018 15.0 Final 23 May 2018 Equity shares
25 May 2017 11.0 Final 29 May 2017 Equity shares
22 Apr 2016 7.5 Final 26 Apr 2016 Equity shares
30 Mar 2015 6.0 Final 06 Apr 2015 Equity shares
10 Mar 2014 8.5 Final 12 Mar 2014 Equity shares
07 Mar 2013 2.5 Final 09 Mar 2013 Equity shares
22 Oct 2010 95.0 Interim 25 Oct 2010 Equity shares
18 Mar 2010 20.0 Final 20 Mar 2010 Equity shares
06 Apr 2009 17.5 Final 09 Apr 2009 Equity shares
04 Apr 2008 10.0 Final 08 Apr 2008 Equity shares
21 Mar 2007 20.0 Final 23 Mar 2007 Equity shares
21 Mar 2007 10.0 Interim 23 Mar 2007 Equity shares
12 Apr 2006 0.0 Final 15 Apr 2006 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
14 Feb 2024 50.0 Interim 14 Feb 2024 Equity shares
14 Feb 2024 150.0 Special 14 Feb 2024 Equity shares
23 Nov 2023 50.0 Final 24 Nov 2023 Equity shares
13 Feb 2023 45.0 Interim 13 Feb 2023 Equity shares
15 Nov 2022 11.5 Final 17 Nov 2022 Equity shares
12 May 2022 41.0 Interim 13 May 2022 Equity shares
02 Nov 2021 40.0 Final 05 Nov 2021 Equity shares
02 Nov 2021 90.0 Special 05 Nov 2021 Equity shares
18 Nov 2020 42.0 Final 20 Nov 2020 Equity shares
18 Nov 2020 188.0 Special 20 Nov 2020 Equity shares
23 May 2019 24.0 Final 25 May 2019 Equity shares
23 May 2019 416.0 Special 25 May 2019 Equity shares
21 May 2018 15.0 Final 23 May 2018 Equity shares
25 May 2017 11.0 Final 29 May 2017 Equity shares
22 Apr 2016 7.5 Final 26 Apr 2016 Equity shares
30 Mar 2015 6.0 Final 06 Apr 2015 Equity shares
10 Mar 2014 8.5 Final 12 Mar 2014 Equity shares
07 Mar 2013 2.5 Final 09 Mar 2013 Equity shares
22 Oct 2010 95.0 Interim 25 Oct 2010 Equity shares
18 Mar 2010 20.0 Final 20 Mar 2010 Equity shares
06 Apr 2009 17.5 Final 09 Apr 2009 Equity shares
04 Apr 2008 10.0 Final 08 Apr 2008 Equity shares
21 Mar 2007 20.0 Final 23 Mar 2007 Equity shares
21 Mar 2007 10.0 Interim 23 Mar 2007 Equity shares
12 Apr 2006 0.0 Final 15 Apr 2006 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

PROCTER & GAMBLE HEALTH L Share Price

Procter & Gamble Health Limited was erstwhile incorporated as E Merck (India) Limited in year 1967. The Company's name was changed from E Merck (India) Limited to Merck Limited on March 27, 2002. Later, the name of the Company was changed to Procter & Gamble Health Limited on 6 May, 2019. The company was set up to take over the business of the Indian branch of Emeda Exports with all their assets and liabilities. The company is a 51% subsidiary of German firm Merck KGaA, is a leading player in vitamin formulations.

Procter & Gamble Health Limited is an Indian-based company principally engaged in the business of manufacturing and marketing of pharmaceuticals and chemicals. The company is the supplier of Pharmaceutical Chemicals, Formulated Chemical Products, Chemicals, Industrial Chemicals, Chemicals, Pharmaceutical Industry, and Chemical Products.

The company offers prescription drugs, biotechnology products, and consumer health products, including over-the-counter products. They also offer products for the treatment of cancer, neurodegenerative diseases, infertility, endocrine and metabolic disorders, cardiovascular diseases, and other conditions with unmet medical needs.

The company operates in two business divisions, namely Pharmaceuticals and Chemicals. The Pharmaceuticals business comprises of Ethicals used in the treatment of Cardiovascular and Metabolic diseases & Vitamin-based formulations and Consumer Health Care Products. The Chemicals business comprises of Bulk Drugs and Pigments. Segment revenue relating to the Chemicals business consists of bulk drugs, pigments and active pharmaceutical ingredients.

The company started their operations as a manufacturer of pharmaceutical specialties and over the years, they have diversified their product range to include basic drugs, fine and industrial chemicals, and diagnostics. In the year 1981, the company became a public limited company they were the first in the Merck group.

In December 2000, the company acquired the Livogen brand from Glaxo India for a consideration of Rs 8 crore. They entered into a co-marketing tie-up with the domestic Pharma Company Kopran for a new anti-inflammatory drug Rofecoxib, in the country. They launched new drug under the brand name of 'Acrobat', while Kopran launched the product under the brand name of 'Ziflam'.

In the year 2002, the company launched Anti-diabetic molecule, namely 'Glimepiride' in the market.

In the year 2004, the company sold their Taloja undertaking to Biochem Pharmaceutical Industries Ltd for a consideration of Rs 100 million. In addition, the Pharma section of the company started a new unit, namely Consumer Health Care to market medicines for common ailments.

In the same year, the company formed a Public Charitable Trust known as 'Merck India Charitable Trust' with the main object of rendering financial assistance to children from the poorer section of society, to pursue primary and secondary education.

In the year 2005, the company increased the production capacity of Bulk Drugs by 18 tonnes to 318 tonnes. They launched a new product, namely Pedimune, which is a formulation to improve the immunity level of Children.

In the year 2006, the company expanded the production capacity of Bulk Drugs by 33 tonnes to 351 tonnes. In April 2006, the Life Science and Analytics (excluding Bulk Drugs) Business (LS&A business) of the Division was sold to Merck Specialities Pvt Ltd. All the assets and rights on the manufacturing and distribution facilities were transferred to Merck Specialities Pvt Ltd.

In the year 2007, the company increased the production capacity of Injection/ Nasal Drops by 24 kilolitres to 427 kiloliters. The Pharmaceuticals segments launched Olmighty Tablets, Evion Forte Tablets, Polybion Complete Syrup, Met Neurobion Injection, Livogen CZ Tablets and Nasivion Care Drops.

In the year 2008, the company expanded the production capacity of Bulk Drugs by 128 tonnes to 479 tonnes, Injection/ Nasal Drops by 13 kiloliters to 440 kiloliters and Tablets/ Capsules by 40 million Nos to 400 million Nos. In addition, they commissioned the project for the substantial expansion of the production capacity of their patented molecule, Oxynex ST. This plant is a 100% export-oriented unit and having a capacity to produce around 150 tonnes per year.

In March 2016, the Health Ministry banned 344 fixed drug combinations through a gazette notification, based on the recommendation of its expert committee. Two drugs produced by the Company were impacted by this ban order. Pharmaceutical companies including the company challenged the order before the Hon'ble Delhi High Court and the Court was pleased to set aside the government notification. The Government may challenge the said decision of the Hon'ble Delhi High Court before Hon'ble Supreme court. Any adverse decision by the higher court or further addition to this list of banned drugs could impact the growth of the pharmaceutical companies. The Company has received a demand notice frorfi National Pharmaceutical Pricing Authority (NPPA) demanding a sum of Rs116.8 million plus interest Rs157.8 million alleging overcharging of price of the formulation Polybion L 100 ML syrup during the period from May 2006 to June 2009. The Company has challenged the said orders by way of a writ petition. In a separate proceedings filed by Cfadel Pharmaceuticals Private Limited, the manufacturer of the said drug, Hon'ble Kolkata High Court granted temporary stay against the demand notice subject to a sum of Rs22.5 million being deposited with NPPA, which the Company has made. The Company has been legally advised it has a good defendable case. The Company has challenged the said orders and will defend itself vigorously, however, any adverse orders by the courts may have material impact on the profits of the Company.

During the year 2016, the Company introduced a new drug Lipigo (Rosuvastatin) which received enthusiatic market response.

During the Financial Year 2018-19, Company launched Whisper Choice Aloe Vera.

The Company launched flagship brand 'Neurobion Forte' in FY 2019-20. It launched the 'New Livogen Iron' and 'Multivitamin Tonic', a comprehensive iron syrup. Polybion launched the New Polybion Active Syrup, a superior B Complex Syrup enriched with Lysine
in a sugar free tasty mango flavour base.

During the year 2019-20, the shareholders of the Company vide their resolution dated June 12, 2018, had approved the execution of a business transfer agreement (BTA) with Merck Life Science Private Limited (MLSPL) to sell, lease or transfer certain businesses of the Company comprising biopharma, performance materials and life science segments (BPL business) to MLSPL , for an overall consideration of Rs 105,200 lakhs on a slump sale basis, which completed in November 30, 2018. And subsequent to this, Company's main business was changed to manufacturing and marketing of pharmaceuticals.

In 2022-23, Company launched variants like Neurobion Alfa & Alfa D for patients with Diabetic Neuropathy.; launched Polybion A injection, a new and improved formulation.

Parent organization MNC Associate
NSE symbol PGHL
Founded 1967
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Procter & Gamble Health Ltd?

Answer Field

The share price of Procter & Gamble Health Ltd for NSE is ₹ 5052 and for BSE is ₹ 5061.

What is the Market Cap of Procter & Gamble Health Ltd?

Answer Field

The market cap of Procter & Gamble Health Ltd for NSE is ₹ 84,35.80 Cr. and for BSE is ₹ 0.0 Cr. as of now.

What is the 52 Week High and Low of Procter & Gamble Health Ltd?

Answer Field

The 52 Week High and Low of Procter & Gamble Health Ltd for NSE is ₹ 5850.00 and ₹ 4639.25 and for BSE is ₹ 5835.95 and ₹ 4640.30.

How to Buy Procter & Gamble Health Ltd share?

Answer Field

You can trade in Procter & Gamble Health Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Procter & Gamble Health Ltd?

Answer Field

The 1 year returns on the stock has been 3.50%.

What is the Current Share Price of Procter & Gamble Health Ltd?

Answer Field

Procter & Gamble Health Ltd share price is for NSE ₹ 5052 & for BSE ₹ 5061 as on Apr 30 2025 03:29 PM.

What is the Market Cap of Procter & Gamble Health Ltd Share?

Answer Field

The market cap of Procter & Gamble Health Ltd for NSE ₹ 84,35.80 & for BSE ₹ 0.0 as on Apr 30 2025 03:29 PM.

What is the P/E Ratio of Procter & Gamble Health Ltd Share?

Answer Field

As on Apr 30 2025 03:29 PM the price-to-earnings (PE) ratio for Procter & Gamble Health Ltd share is 35.59.

What is the PB ratio of Procter & Gamble Health Ltd Share?

Answer Field

As on Apr 30 2025 03:29 PM, the price-to-book (PB) ratio for Procter & Gamble Health Ltd share is 367.76.

How to Buy Procter & Gamble Health Ltd Share?

Answer Field

You can trade in Procter & Gamble Health Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Procter & Gamble Health Ltd Share on Bajaj Broking App?

Answer Field

To buy Procter & Gamble Health Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Procter & Gamble Health Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|